Cargando…
Lovastatin Inhibits VEGFR and AKT Activation: Synergistic Cytotoxicity in Combination with VEGFR Inhibitors
BACKGROUND: In a recent study, we demonstrated the ability of lovastatin, a potent inhibitor of mevalonate synthesis, to inhibit the function of the epidermal growth factor receptor (EGFR). Lovastatin attenuated ligand-induced receptor activation and downstream signaling through the PI3K/AKT pathway...
Autores principales: | Zhao, Tong T., Trinh, Diane, Addison, Christina L., Dimitroulakos, Jim |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2933231/ https://www.ncbi.nlm.nih.gov/pubmed/20838437 http://dx.doi.org/10.1371/journal.pone.0012563 |
Ejemplares similares
-
Combined VEGFR and MAPK pathway inhibition in angiosarcoma
por: Wagner, Michael J., et al.
Publicado: (2021) -
Rutacecarpine Inhibits Angiogenesis by Targeting the VEGFR2 and VEGFR2-Mediated Akt/mTOR/p70s6k Signaling Pathway
por: Ji, Lijun, et al.
Publicado: (2018) -
Computational Modeling to Quantify the Contributions of VEGFR1, VEGFR2, and Lateral Inhibition in Sprouting Angiogenesis
por: Kühn, Clemens, et al.
Publicado: (2019) -
Lovastatin Induces Multiple Stress Pathways Including LKB1/AMPK Activation That Regulate Its Cytotoxic Effects in Squamous Cell Carcinoma Cells
por: Ma, Laurie, et al.
Publicado: (2012) -
VEGFR-2 reduces while combined VEGFR-2 and -3 signaling increases inflammation in apical periodontitis
por: Virtej, Anca, et al.
Publicado: (2016)